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Biological markers of intermediate health outcomes sometimes provide a superior alternative to traditional measures of pollutant-related disease.
Some opportunities and methodologic issues associated with using markers are discussed in the context of exposures to four complex mixtures:
environmental tobacco smoke and nitrogen dioxide, acid aerosols and oxidant outdoor pollution, environmental tobacco smoke and radon, and
volatile organic compounds. For markers of intermediate health outcomes, the most important property is the positive predictive value for clinical
outcomes of interest. Unless the marker has a known relationship with disease, a marker response conveys no information about disease risk. Most
markers are nonspecific in that various exposures cause the same marker response. Although nonspecificity can be an asset in studies of complex
mixtures, it leads to problems with confounding and dilution of exposure-response associations in the presence of other exposures. The timing of a
marker's measurement in relation to the occurrence of exposure influences the ability to detect a response; measurements made too early or too
late may underestimate the response's magnitude. Noninvasive markers, such as those measured in urine, blood, or nasal lavage fluid, are generally
more useful for field studies than are invasive markers. However, invasive markers, such as those measured in bronchoalveolar lavage fluid or lung
specimens from autopsies, provide the most direct evidence of pulmonary damage from exposure to air pollutants. Unfortunately, the lack of basic
information about marker properties (e.g., sensitivity, variability, statistical link with disease) currently precludes the effective use of most markers in
studies of complex mixtures. - Environ Health Perspect 101 (Suppl 4):193-197 (1993).
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Introduction
Most studies ofhealth effects in humans ex-
posed to complex air-pollutant mixtures
have used such outcome measures as hospi-
tal admission rates during air pollution
episodes, symptom reports from question-
naires or diaries, and disease prevalence or
mortality rates in communities with differ-
ent levels ofair pollutants. A few studies in
controlled exposure settings have attempted
to assess the combined as well as separate ef-
fects of mixture components. Such ap-
proaches provide useful information; but
studies ofovert disease often are insensitive
to low-dose exposure effects, and they
focus on the extreme end of the disease
spectrum, where only a small proportion of
the exposure-related disease burden occurs.
Biological markers ofintermediate health
outcomes (i.e., early pathologic changes or
events predictive ofdisease) could provide a
superior alternative to traditional measures of
pollutant-related disease. Markers can have
greater sensitivity to exposure effects, they
may appear sooner after exposure and at
younger ages, and they may detect a greater
proportion of the exposure-related disease
burden compared to measures used in the
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past. Because some early pathologic changes
detected by markers do not progress to
symptomatic conditions, more people will
show positive marker responses than overt
disease; so studies using markers can poten-
tially have increased statistical power due to
the more numerous outcomes. However, the
markers are useful only to the extent that
they have a known relationship to clinical
diseases ofinterest.
In general, biological markers are indica-
tors ofevents occurring in the body that are
difficult to measure directly. Markers can in-
dicate that an exposure, a response to expo-
sure, or an early pathologic change has
occurred; other markers, often enzyme phe-
notypes, indicate an individual's increased
susceptibility to disease from a particular ex-
posure. Such markers differ from genetic
markers, which are usually defined in the
current genetic literature as discrete pheno-
types controlled by genes that occur in close
proximity on chromosomes to other genes
of interest. A good genetic marker will be
correlated highly with the presence of the
geneofinterest, which maybe undetectable.
The following presentation discusses
some methodologic issues associated with
the use ofbiological markers ofintermedi-
ate health outcomes arising from exposures
to complex pollutant mixtures. In most in-
stances, this article focuses on outcomes re-
lated to four examples of complex mix-
tures: a) environmental tobacco smoke
(ETS) and nitrogen dioxide (NO2), b) acid
aerosols and oxidant outdoor pollution, c)
ETS and radon, and d) volatile organic
compounds (VOCs). No standard defini-
tion exists for the term biological marker.
For example, the National Research Coun-
cil's (NRC) 1989 book BiologicMarkers in
Pulmonary Toxicology (1) defines biological
markers as "indicators ofevents in biologic
systems or samples," while others [e.g.,
Hulka et al. (2)] limit the definition to in-
dicators measured in biological specimens
obtained from a person. The NRC defini-
tion includes, for example, spirometry,
which involves no assays ofbiological sam-
ples. This discussion uses the more restric-
tive definition of Hulka et al. (2). These
two references provide additional informa-
tion about markers in general and about




marker of effect is its link with the health
outcome ofinterest. Although markers in a
target tissue (i.e., tissues that give rise to the
disease ofinterest) usually provide the best
early indicator of an adverse event, markers
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outside of the pathogenic pathway can be
superior for avariety ofreasons. For example,
target tissues such as the lung are relatively
inaccessible, markers in the target tissue may
require higher exposures to show a response
than do markers in a nontarget tissue, and
markers in a target tissue may have less
persistence due to rapid cell turnover or other
mechanisms ofmarkerloss.
Astudy ofmicronudei measured in exfo-
liated epithelial cells in sputum of uranium
workers exposed to radon and tobacco smoke
illustrates how markers outside ofthe patho-
genic pathway can show a stronger statistical
association with the disease under considera-
tion. Micronudei, which arecaused byagents
that damage DNA, are small secondary nu-
dei formed during mitosis when whole chro-
mosomes or chromosome fragments fail to
become incorporated into daughternuclei. As
summarized by Loomis et al. (3), the mi-
cronucleus assay in exfoliated buccal cells is
sensitive to ionizing radiation as well as to-
bacco smoke; uranium miners show a clear
radon-related excess oflung cancer, but nei-
ther radon exposure nor cigarette smoking
wasassociatedwith ahigherprevalence ofmi-
cronuclei in Loomis's study ofsputum cells
from the miners. In contrast, other studies of
uranium miners (4) and persons with resi-
dential radon exposure (5,6) show increased
levels ofstructural chromosome aberrations
in blood lymphocytes. Although chromo-
some aberrations in lymphocytes have no di-
rect role in lungcancer, their association with
radon exposure suggests that this marker,
compared to micronudei in sputum cells, has
a stronger statistical link with lung cancer
arisingfrom radon exposure.
Other markers ofpremalignant changes
with potential interest for studies ofcarcino-
genic exposures (e.g., VOCs or radon and
ETS) include sputum cytology, the hypox-
anthine-guanine phosphoribosyl transferase
(HGPRT) assay for in vivo mutations, and
assays of oncogene activation. To date,
human studies using the HGPRT assay pri-
marily have examined peripheral lympho-
cytes, but the assay could be adapted for
pulmonary macrophages obtained through
bronchoalveolar lavage (BAL) (1). By using
macrophages, the marker would detect mu-
tations occurring in the lung, although lung
tumors do not arise from macrophages
themselves. Theoretically, activated onco-
genes could be detected in exfoliated cells in
lavage fluid to characterize developing lung
tumors (1). The use ofalmost any marker
ofintermediate outcomes would increase the
number ofexposure-related outcomes (com-
pared to the number ofcancers) in the study
while reducing the necessary time interval
between exposure and measurement of the
outcome. At this point, however, most
markers of intermediate outcomes have an
unknown relationship to clinical disease; so
theirvalue is limited.
The rationale for using nontarget tis-
sues and cells for assessing evidence ofearly
disease is that pathologic changes observed
in nontarget tissues often occur in the tar-
get tissues. For example, exposure to acid
aerosols and oxidants can exacerbate airway
hyperreactivity in asthmatics (1), with a re-
sulting increase in pulmonary and blood
eosinophils. Chronic deposition of
eosinophils in the lung may cause airway
inflammation, but eosinophils are much
easier to measure in blood than in the lung.
Even ifmarkers in target tissues compared
to nontarget tissues do show a stronger as-
sociation with the ultimate outcome of in-
terest, their inaccessibility may preclude
their use in observational studies.
In general, the selection of markers in-
volves a tradeoff between a marker's posi-
tive predictive value for the disease and such
practical issues as specimen availability,
marker sensitivity, and assay cost. Unfortu-
nately, many potentially useful markers
have an unknown relationship to lung dis-
ease. For example, the relationship between
changes in constituents ofBAL fluid (a po-
tential source ofmyriad markers ofinterme-
diate outcomes) and pollutant-induced
injury requires further study (1). Markers
of events that occur further down the dis-
ease pathway, such as fibrosis, moderate air-
space enlargement, or mutations, have
clearer biological links with dinically appar-
ent disease. In the absence ofimportant ad-
vantages associated with other markers,
biologically plausible markers having obvi-
ous biological links with disease are prefer-
able to markers without such links. The
validity of markers that occur in nontarget
tissues or early in the pathogenic process
would be assessed ideally in prospective
studies, where their positive predictive value
for subsequent overt disease can be esti-
mated. Such studies would be difficult, es-
pecially when cancer is the outcome of
interest, because ofthe need for large study
populations andlongfollow-up periods.
Studies of associations that can be
measured cross-sectionally are more feasible.
One could, for example, ascertain whether a
marker measured in blood has a high
positive predictivevalue for inflammation in
the lung. A marker with a high predictive
value for inflammation could be used as an
outcome variable in a study to determine
whether exposure to a complex mixture
causes inflammation.
SpecificityandConfounding
Some markers respond to specific environ-
mental exposures, while others respond to a
wide variety of agents. For studies of com-
plex mixtures, nonspecificity can be an asset,
because the marker response will reflect the
combined effects of multiple, sometimes
unidentified, agents. Furthermore, the air-
ways can react to inhaled toxic materials in a
limited number ofways, so awide variety of
exposures lead to a small number of health
effects. For example, many inhaled toxi-
cants, such as acid aerosols and oxidant gases
like NO2 and ozone, cause inflammation in
the respiratory tract. Exposure to ETS and
NO2 in children increases the riskofrespira-
tory infections, which also cause inflamma-
tion. Chronic or repeated inflammation may
in turn lead to irreversible lung injury and,
eventually, clinically apparent diseases such
as emphysema. Therefore, indicators of in-
flammation or early loss of elasticity can
serve as markers of intermediate outcomes
from numerous exposures, the effects of
which converge on a common pathologic
pathway.
The convenience ofusing a nonspecific
marker that responds to a variety of com-
plex mixtures is offset by the possibility of
dilution and confounding from exposures
other than those ofinterest. As discussed by
Weiss and Liff (7), the problem of dilu-
tion, where an exposure-response associa-
tion is obscured by other associations, arises
when different causal pathways lead to the
same end point, as is the case with nonspe-
cific markers of intermediate outcomes. If
two different exposures (or sets of expo-
sures), E1 and E2, cause the same marker re-
sponse through independent pathways, they
increase the overall marker response rate in
an additive manner; but relative measures of
association (e.g., relative risk, odds ratio,
etc.) are based on the assumption ofa mul-
tiplicative model ofassociation. As a result,
the relative risk of the response due to El
will be influenced by the background inci-
dence ofthe response due to E2. In this sit-
uation, use ofthe risk difference rather than
relative risk to compare marker responses in
persons exposed and unexposed to E1 helps
avoid the problem ofdilution from a high
background incidence from E2.
Another strategy for mitigating the
problem ofdilution is to stratify an overall
group ofend points into its more homoge-
neous components (7). Inflammation from
different exposures, for example, may have
slightly different manifestations detectable
by different markers. Each marker would
have greater specificity for a given exposure
than would a marker that detected overall
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inflammation. The feasibility of this ap-
proach for studies of complex mixtures is
unclear until additional basic information
on properties of markers of intermediate
outcomes becomes available.
Weiss and Liff(7) point out that studies
of intermediate outcomes sometimes facili-
tate the identification of a particular causal
pathway. For example, if exposure to one
complex mixture leads to pulmonary disease
through inflammation, while another expo-
sure causes the same disease through a non-
inflammatory process, the complex mixture
would show a stronger association with in-
flammation than with the pulmonary dis-
ease. However, this approach is feasible only
when the intermediate outcome has a
known relationship to the clinical outcome
ofinterest-a rare situation.
Confounding could arise in studies of
inflammation due to exposure to acid
aerosols and oxidants, for example, if ex-
posed persons tend to be heavy smokers or
have occupational exposures that also cause
inflammation. Problems with confounding
are essentially the same whether one uses
nonspecific markers of intermediate out-
comes or actual diseases as study end points.
The usual epidemiologic approaches for
controlling confounders (i.e., stratified
analysis, matching, or restriction) can re-
move the effects ofextraneous variables. Ex-
posure-specific markers would be less prone
to confounding than would nonspecific
markers, but outcome markers that arise
only from single agents would have limited
value forstudies ofcomplex mixtures.
Sensiiity
In many instances, different markers can be
used to detect the same outcome. Inflam-
mation, for example, involves numerous
physiological changes that can be used as
markers ofthe inflammatory response. For
a given degree of inflammation, however,
some markers will be easier to detect than
will others. Markers that detect the mildest
inflammation (i.e., those that are positive
with the lowest exposures) would have the
greatest sensitivity.
An animal study (8) illustrates several
issues associated with marker sensitivity for
intermediate outcomes. The investigators
evaluated different markers of connective
tissue metabolism (a response to injury in
the lung) in urine or BAL fluid. In one ex-
posure protocol using 0.5-ppm NO2 expo-
sure for 4 weeks, hydroxylysine urinary
excretion increased significantly, but levels
of hydroxylysine and angiotensin-convert-
ing enzyme activity in lavage fluid remained
normal and lunghistology showed no dam-
age. Compared to other markers of effects
on connective tissue, urinary hydroxylysine
apparently has greater sensitivity.
Although this controlled study ofNO2
exposure in rats only has indirect relevance
to free-living human populations exposed
to complex mixtures, it does illustrate that
different markers vary in sensitivity, and
that the same marker measured in different
biological materials also can have different
sensitivities. For reasonably benign expo-
sures, such as many commonly occurring
complex mixtures, exposure chamber stud-
ies can characterize a promising marker's
properties (e.g., sensitivity, dose-response,
and interindividual and intraindividual
variability) in humans under controlled
conditions. These studies can evaluate
markers ofacute outcomes but precise esti-
mates ofsuch properties will rarely, ifever,
be available for marker responses from
chronic exposures.
In general, a marker's sensitivity and
positive predictive value can be increased
by studying susceptible populations. For
example, exposure to acid aerosols-oxi-
dants can exacerbate symptoms of asthma.
Sensitized asthmatics compared to nonsen-
sitized asthmatics and nonasthmatics are
likely to show an inflammatory response at
lower exposure levels, so markers ofinflam-
mation will have greater sensitivity in stud-
ies of sensitized asthmatics. Similarly,
ETS-NO2 exposure may increase the risk
of respiratory infections in children more
than in adults, possibly through alterations
in immune function; theoretically, markers
ofsuch alterations may have a greater sensi-
tivity (i.e., occur at relatively low exposure
levels) in children given their apparent in-
creased susceptibility to infections compared
to adults. Given the known susceptibility of
such groups as asthmatics and children to
some mixtures, they also maybe susceptible
to other pollutant mixtures, so that adverse
health outcomes and associated markers
could be detected at relatively low exposure
levels.
Sensitivity also can be increased for a
given ambient concentration by studying
people with a relatively high internal dose
ofa pollutant mixture, such as those having
a high rate of ventilation due to physical
activity. Persons who spend a large propor-
tion of time outdoors also will have rela-
tively high doses of ambient outdoor air
pollutants. Thus, for a given exposure level,
marker responses would probably be more
pronounced in persons with biological sus-
ceptibility and in those with behaviors that
increase either their internal dose or their
contactwith ambient pollutants.
TemporalAspects
Markers can appear hours, days, or years
after exposure. For example, nasal irritation
is commonly associated with indoor air
pollution (e.g., VOCs and other complex
mixtures). Markers of cell and mediator
changes in nasal lavage fluid could be use-
ful for studies of such pollutants (1), and
the markers would probably appear within
hours of exposure. In contrast, several
months or years of exposure to acid
aerosols and oxidants may be necessary to
detect airspace enlargement using mor-
phometry, while changes in alveolar cell
populations may appear after days or weeks
ofexposure.
For transient markers, the timing of
measurements is especially crucial. The in-
flux ofneutrophils and eosinophils into the
respiratory tract, for example, usually oc-
curs during the first 3 to 7 days of an in-
flammatory response (1). Measurements of
these markers of inflammation in BAL
fluid immediately after exposure would un-
derestimate the inflammatory response, as
would measurements taken after the re-
sponse subsided. Protein influx reflecting
pulmonary epithelial damage, however,
should be measured relativelysoon after ex-
posure. For sustained ongoing exposures,
such as occurs with VOCs or residential
radon exposure and ETS, transient markers
will be replenished, and measurements can
be made any time during seasons when
buildings are likelyto be poorlyventilated.
The timing of measurements is less
important for markers of chronic expo-
sure-related changes. Irreversible airspace
enlargement, for example, can be measured
long after exposure ends, and it will reflect
cumulative exposureeffects.Alteredpopula-
tions ofalveolar epithelial cells due to oxi-
dantairpollution exposureeventually revert
to normal proportions, but these markers
can probably be detected for at least several
weeks after the end ofexposure. Timing is
still important in the sense thattheexposure
must be sufficiently long for the marker
response to occur. Note thatforsomemark-
ers ofchronic pathogenic processes, such as
themarkers ofconnective tissuedegradation
in the study by Evans et al. (8), the marker
responsediminishes afterthe exposurestops




The effective use of a marker in epidemio-
logic studies of complex mixtures depends
not only on the marker's properties but also
on the availability ofsuitable biological ma-
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terials and moderately priced assays. Nu-
merous markers of intermediate outcomes
are inappropriate for field studies because of
their invasive nature. The following section
mentions some noninvasive markers with
potential usefulness for studying complex
mixtures, and it discusses strategies for using
invasive markers.
NoninvasiveMarkers
In general, markers measured in such materi-
als as urine, sputum, blood, and nasal lavage
fluid are well suited for field studies because
specimen collection involves relatively little
inconvenience or risk for study participants.
Urine could be valuable especially for studies
ofETS and NO2. ETS exposure can be esti-
mated from urine samples, as can some
markers of connective tissue metabolism as-
sociated with NO2 exposure. Sputum cytol-
ogy, a marker of disease that is nonspecific
with regard to exposure, may reveal earlyevi-
dence ofcarcinogenic changes from such ex-
posure as VOCs or ETS and radon gas.
Standardization of sputum collection and
preparation might alleviate the problems en-
countered by Loomis et al. (3) and allow de-
tection of increased micronudei from these
exposures. Loomis et al., who used archived
specimens, could not control the source of
sputum and its cellular content; and labora-
tory manipulation of the old samples may
have caused aloss ofsomecell structures.
Blood is a source of numerous and di-
verse markers. As noted earlier, radon expo-
sure at levels that increase the risk oflung
cancer are associated with chromosome ab-
normalities in blood lymphocytes. Markers
ofaltered immune function, which increases
the risk ofrespiratory infections, also can be
measured in blood. Some studies suggest
that markers of pulmonary hypertension,
which apparently is caused by several toxic
chemicals, also may be present in blood (1);
possible markers include elevated plasma
copper levels and ristocetin cofactor activity
relative to plasmavonWillebrand factor.
Many changes in constituents of blood
and nasal lavage fluid reflect the changes
that occur in less accessible BAL fluid. For
example, the distribution of lymphocyte
subpopulations, a marker of air pollution
effects, is similar in blood and BAL fluid
(1). Nasal lavage fluid, which contains sev-
eral markers that respond to a variety of
constituents found in complex mixtures,
may be especially useful in studies ofindoor
air pollutants that cause nasal irritation (1).
Comparisons between markers in nasal and
BAL fluid are necessary to ascertain the use-
fulness ofnasal lavage markers as indicators
ofevents in the lower respiratory tract.
InvasiveMarkers
Someofthemostinformativemarkersofinter-
mediate outcomes occurin relativelyinaccessi-
blebiological materials such as thelung. One
approachto obtaininglungspecimens is BAL,
which uses amodified bronchoscope forcol-
lectingpulmonarycellsandfluids. Lavagefluid
contains a variety ofbiological materials in
whichtomeasuremarkersofintermediateout-
comes. Themethodisusedprimarilyfordiag-
nostic purposes and in controlled-exposure
chamberstudies. Although its invasive nature
precludes the routineuseofBALin fieldstud-
ies, small studies ofindividualswithexposures
to naturallyoccurringcomplexmixtures could
detect numerous potential exposure-related
effects. The use ofpersonal monitors in con-
junctionwithlavagemeasurementswouldpro-
vide ahigh degree ofprecision in estimates of
exposure-outcome associations. Retrospective
collaborativestudiesusingarchivedlavagespec-
imens also maybe feasible ifunexposed con-
trols from chamber studies in cities having
differentlevels ofairpollutioncouldbe identi-
fied. Differences in specimen collection and
storage amongresearch centers, however, may
precludesuchretrospective studies.
Much ofthe recent animal research and
some human studies of air pollution have
used morphometric measurements for assess-
ing pulmonary damage. The morphometric
approach uses an overlay of points or lines
that is placed over an electron micrograph or
other two-dimensional image of a lung sec-
tion. By estimating the proportion ofpoints
or numbers oflines that fall on cell or airway
structures, one can use a set offormulas to
estimate various cell and tissue parameters,
such as cell size and structure, proportions of
cell types, orairwaydiameters (9).
Morphometric studies oflung tissue are
limited to specimens obtainedfromsurgeryor
autopsy. This severeconstraintraises ahostof
methodologic problems, but the potential
value ofmorphometric measurements argues
in favor offurther exploring this promising
technique. For example, morphometry has
been used to studypostnatal lunggrowth (1),
an outcome relevant to ETS-NO2 exposur;
and numerous morphometric studies have
found pulmonary changes in animals exposed
to single pollutants and pollutant mixtures
(10). Limited studies ofair pollution using
morphometrywithhuman autopsyspecimens
point to thefeasibilityofmovingfrom animal
to human tissues. The application of mor-
phometric techniques to human lung speci-
mens may eventually provide the most direct
evidence ofpulmonary damage from chronic
low exposures to complex mixtures. How-
ever, basic work remains to be done. Studies
are necessary to describe lung lesions in per-
sons ofdifferent ages exposed to ubiquitous
background pollutants (ETS, automobile ex-
haust, etc.) and to investigate the effects on le-
sion measurement ofdifferent protocols for
collecting, handling, and storing lung spec-
imens in autopsy settings.
Conclusion
Indoor and outdoor airpollutants potentially
can affect the health ofvirtually everyone in
the United States. Animal studies usingcon-
trolled chronic exposures are important for
identifying the pollutants responsible for
adverse health effects, but epidemiologic
studies address the effects of complex
pollutant mixtures that actually occur in ex-
posed humans. Biological markers ofinter-
mediate outcomes offer new opportunities
foradvancing thestudyofthesepollutants.
Unfortunately, many research opportuni-
ties associated with markers remain theoreti-
cal. Much basic information critical for valid
application ofmarkers is lacking. For exam-
ple, few markers have been characterized re-
garding their statistical properties, such as
assayvariability andvariability in samples col-
lected from the same individual at different
times. Furthermore, protocols for collecting,
storing, and analyzing biological specimens
have not been standardized. More important,
the relationship between markers ofinterme-
diate outcome and dinical disease remains a
matter ofspeculation. Invesigators studying
exposures to complex mixtures therefore can-
notinterpret the health implications ofaposi-
tivemarkerresponse, norcan theyconfidently
attribute a lack ofan exposure-response asso-
ciation to a true absence ofa biological effect
when a marker's sensitivity and variability are
unknown. Also, the nonspecific nature of
currently used markers of intermediate out-
comes leads to potential problems with dilu-
tion and confounding ofexposure-outcome
associations. Acombination ofcontrolled ex-
posure studies and systematically conducted
epidemiologic studies could readily address
the validity issues, but the high cost ofmany
marker assays discourages their use in
large-scaleepidemiologicstudies.
Progress in applyingmarkers to studies of
human exposures and diseases requires
considerable effort from both toxicologists
andepidemiologists. However, neithergroup
has great incentive to undertake the mundane
systematic studies necessary to characterize
marker properties in a statistically valid
manner: bench scientists usually prefer to
investigate promising new techniques while
epidemiologists are primarily interested in
etiologic associations. Progress in the use of
markers is likelyto occur slowlyuntil answers
to basicquestions becomeavailable. G
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